Bradykinin B1 receptors in human umbilical vein

https://doi.org/10.1016/S0014-2999(96)00927-2Get rights and content

Abstract

The present study was undertaken to demonstrate the presence of bradykinin B1 receptors mediating contraction of human umbilical vein. The bradykinin B1 receptor selective agonist, des-Arg9-bradykinin, produced a dose-dependent contractile response of human umbilical vein rings. Furthermore, des-Arg9-bradykinin-mediated response increased in a time-dependent manner in vitro. The maximal response to des-Arg9-bradykinin, expressed as percentage of the maximum elicited by serotonin, was: 10 ± 2 at 15 min, 55 ± 5 at 120 min and 80 ± 3 at 300 min. Des-Arg9-bradykinin-mediated contractions were inhibited by the specific bradykinin B1 receptor antagonist des-Arg9-[Leu8]bradykinin which produced parallel shifts in the dose-response curve to the selective bradykinin B1 receptor agonist. Schild regression analysis of data established a pA2 value of 6.16 ± 0.06. Kinin-induced contraction was not modified by pre-treatment with indomethacin (10 μM), a cyclo-oxygenase inhibitor. On the other hand, continuous exposure to the anti-inflammatory steroid dexamethasone (100 μM) or to the protein synthesis inhibitor cycloheximide (70 μM) largely prevented the sensitization to des-Arg9-bradykinin in incubated human umbilical vein rings. These results confirm the presence of bradykinin B1 receptors which mediate contraction in isolated human umbilical vein. These responses are up-regulated in a time- and protein synthesis-dependent process.

References (27)

  • O. Arunlakshana et al.

    Some quantitative uses of drug antagonists

    Br. J. Pharmacol. Chemother.

    (1959)
  • J. Bouthillier et al.

    Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo

    Br. J. Pharmacol.

    (1987)
  • S.K. Butt et al.

    Bradykinin B1 receptors in the rabbit urinary bladder: induction of responses, smooth muscle contraction, and phosphatidylinositol hydrolysis

    Br. J. Pharmacol.

    (1995)
  • Cited by (41)

    • Argentinean Society of Experimental Pharmacology: Brief history and main scientific contributions to the discipline

      2016, Pharmacological Research
      Citation Excerpt :

      He also started his career in the group of Prof. S. Langer’s. His contribution to Pharmacology is currently based in pharmacodynamics mechanistic studies about the prostanoids and other substances (Bradykinin B1 receptor) using the model of the human umbilical vein [107–112]. Prof. Carlos Lanusse.

    • Prenatal hypoxia enhanced angiotensin II-mediated vasoconstriction via increased oxidative signaling in fetal rats

      2016, Reproductive Toxicology
      Citation Excerpt :

      Sixty minutes were allowed for equilibration. 5-HT (10 mM) was applied for each experiment in order to determinate the tissue maximum response [17]. Vessel rings were contracted with cumulatively increasing concentrations of Ang II (10−11−10−5 mol l−1) in approximate one-half log increments.

    • Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: An effective bradykinin inactivation pathway

      2011, European Journal of Pharmacology
      Citation Excerpt :

      Aminopeptidase P (Xaa-Pro aminopeptidase, EC 3.4.11.9) inactivates bradykinin by hydrolyzing the N-terminal Arg1-Pro2 bond (Simmons and Orawski, 1992). In our human umbilical vein and artery experimental models, bradykinin induces a potent and efficacious vasoconstriction action mediated by bradykinin B2 receptors (Pelorosso et al., 2007; Sardi et al., 1997). Since bradykinin is very short-lived due to extensive enzymatic degradation and its actions on vascular levels are suggested to be of utmost importance, the aim of the present work was to evaluate, by means of functional assays in isolated human umbilical vein, the possible participation of angiotensin-converting enzyme, neutral endopeptidase and aminopeptidase P as a bradykinin inactivating pathway, as well as assess if the endothelial layer is involved in this process.

    View all citing articles on Scopus
    View full text